BioSpace News Archive

Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period ended September 30, 2022.

Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in November.

ACELYRIN, INC. announced two executive appointments that will strengthen leadership of key corporate functions as the company enters its next stage of growth: Mardi C. Dier joins as Chief Financial Officer and Chief Business Officer while Mina Kim joins as Chief Legal and Administrative Officer.

IMV Inc., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced its financial and operational results and provided an update for the third quarter ended September 30, 2022.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer, will participate at Craig-Hallum’s 13th Annual Alpha Select Conference on Thursday, November 17, 2022.

Atreca, Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments.

Chimerix issued the following statement regarding a press release issued by Rubric Capital Management:

PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its board of directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported financial results for its fiscal year 2023 second quarter ended September 30, 2022 and provided a corporate update.